ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.

[1]  O. Tournilhac,et al.  State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 , 2019, Journal of Immunotherapy for Cancer.

[2]  Giri N. K. Rangan,et al.  Committee , 2019, 2019 International Conference on Radar, Antenna, Microwave, Electronics, and Telecommunications (ICRAMET).

[3]  M. Šimkovič,et al.  Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation? , 2018, Archives of medical science : AMS.

[4]  T. Calimeri,et al.  Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. , 2017, The Lancet. Haematology.

[5]  T. Shanafelt,et al.  Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Larocca,et al.  Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Castillo,et al.  Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  R. Marasca,et al.  Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study , 2016, Leukemia & lymphoma.

[9]  W. Klapper,et al.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.

[10]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[11]  A. Bazargan,et al.  Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy , 2016, Leukemia & lymphoma.

[12]  D. Eyre,et al.  Results of a large retrospective analysis of the effect of intended dose intensity of R‐CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma , 2016, British journal of haematology.

[13]  M. Hallek,et al.  Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group , 2016, Leukemia & lymphoma.

[14]  Nibedita Bandyopadhyay,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[15]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[16]  Sonali M. Smith,et al.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.

[17]  R. Stauder,et al.  Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management , 2015, Drugs & Aging.

[18]  W. Hiddemann,et al.  Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study , 2015 .

[19]  P. Gaulard,et al.  Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[21]  E. Kimby,et al.  Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial , 2015, The Lancet.

[22]  G. Colditz,et al.  Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. , 2015, Journal of geriatric oncology.

[23]  F. Cavalli,et al.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.

[24]  M. Aapro,et al.  Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. , 2015, Journal of geriatric oncology.

[25]  Lei Nie,et al.  FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma , 2015, Clinical Cancer Research.

[26]  Thomas E. Hughes,et al.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[27]  H. Wildiers,et al.  Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Mathoulin-Pélissier,et al.  Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study , 2014, PloS one.

[29]  M. Šimkovič,et al.  Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group , 2014 .

[30]  S. Mulligan,et al.  A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity , 2014 .

[31]  M. Piccart,et al.  Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics". , 2014, Journal of the National Cancer Institute.

[32]  Sonali M. Smith,et al.  Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Ziepert,et al.  Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Montserrat,et al.  Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model , 2014, Haematologica.

[35]  Bingshu E. Chen,et al.  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Pfreundschuh,et al.  Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  S. Ferrero,et al.  How to treat old MCL patients: one size fits it all? , 2014, Blood.

[39]  H. Wildiers,et al.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Rao,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older adults. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Šálek,et al.  A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent , 2014, PloS one.

[42]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[43]  Carolyn M. Reilly,et al.  Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. , 2014, Journal of the National Cancer Institute.

[44]  J. Burke,et al.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.

[45]  C. Rübe,et al.  Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[47]  C. Reyes,et al.  Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database , 2014, Annals of Hematology.

[48]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[49]  B. V. van Munster,et al.  On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[51]  H. Döhner,et al.  Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials , 2014, Haematologica.

[52]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[53]  J. Radford,et al.  De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  N. Schmitz,et al.  Suboptimal dosing of rituximab in male and female patients with DLBCL. , 2014, Blood.

[55]  A. Ravaud,et al.  Functional decline in older patients with cancer receiving first-line chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  S. Mathoulin-Pélissier,et al.  Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: a systematic review. , 2013, Cancer treatment reviews.

[57]  P. Gaulard,et al.  Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial , 2013, Haematologica.

[58]  Murielle Mauer,et al.  End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[60]  P. Fayers,et al.  International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer , 2013, British Journal of Cancer.

[61]  A. Hagenbeek,et al.  90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Catherine Thieblemont,et al.  Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[63]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[64]  D. Cunningham,et al.  Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. , 2013, Journal of geriatric oncology.

[65]  G. Pizzolo,et al.  Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[69]  H. Döhner,et al.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  S. Mathoulin-Pélissier,et al.  Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  J. Delabie,et al.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  B. Coiffier,et al.  Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. , 2012, The Lancet. Oncology.

[73]  P. Mclaughlin,et al.  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.

[74]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  R. Talamini,et al.  Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. , 2012, The oncologist.

[76]  M. Coleman,et al.  Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen , 2012, Hematology.

[77]  M. Groenvold,et al.  Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice , 2012 .

[78]  E. Blot,et al.  Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial. , 2011, Critical reviews in oncology/hematology.

[79]  H. Wildiers,et al.  EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[81]  F. Jardin,et al.  Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. , 2011, The Lancet. Oncology.

[82]  H. Cohen,et al.  Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  B. Nathwani,et al.  Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. , 2011, Blood.

[84]  P. Korkolopoulou,et al.  Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen , 2011, Leukemia & lymphoma.

[85]  A. Rosenwald,et al.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.

[86]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[88]  R. Advani,et al.  Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) , 2010, British journal of haematology.

[89]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  M. Gönen,et al.  Characterization of T-cell lymphomas by FDG PET/CT. , 2010, AJR. American journal of roentgenology.

[91]  R. Venkitaraman,et al.  Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15. , 2010, European journal of cancer.

[92]  J. Briones,et al.  Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  E. Montserrat,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  P. Ganly,et al.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  D. Lacombe,et al.  EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. , 2010, Cancer treatment reviews.

[96]  Murielle Mauer,et al.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. , 2009, The Lancet. Oncology.

[97]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  D. Weisenburger,et al.  The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  J. Cerhan,et al.  Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  M. Piris,et al.  Peripheral T-cell Lymphoma With Follicular T-cell Markers , 2008, The American journal of surgical pathology.

[101]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[103]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[104]  G. Jenkins,et al.  Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia , 2008, Leukemia & lymphoma.

[105]  K. Höffken,et al.  Quality-of-life in elderly patients with cancer: a short review. , 2007, European journal of cancer.

[106]  Sukjoong Oh,et al.  Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study , 2007, Cancer Chemotherapy and Pharmacology.

[107]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  C. Copie-Bergman,et al.  Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence That AITL Derives From Follicular Helper T Cells , 2006, The American journal of surgical pathology.

[109]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  A. Hagemeijer,et al.  Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma , 2005, British journal of haematology.

[111]  M. Ghielmini,et al.  Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  R. Yancik,et al.  Cancer in older persons: an international issue in an aging world. , 2004, Seminars in oncology.

[113]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[115]  E. Noordijk,et al.  Different age limits for elderly patients with indolent and aggressive non‐Hodgkin lymphoma and the role of relative survival with increasing age , 2000, Cancer.

[116]  J. Coebergh,et al.  Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996 , 1999, Annals of Hematology.

[117]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  D. Cella,et al.  Age and clinical decision making in oncology patients. , 1994, Journal of the National Cancer Institute.

[119]  C. Sherbourne,et al.  The RAND 36-Item Health Survey 1.0. , 1993, Health economics.

[120]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[121]  J. Ware,et al.  International quality of life assessment (IQOLA) project , 1992, Quality of Life Research.

[122]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[123]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[124]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  S. Pileri,et al.  Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. , 2017, The Lancet. Haematology.

[126]  Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies). , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[127]  F. Jardin,et al.  Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. , 2017, The Lancet. Haematology.

[128]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  P. Fayers,et al.  Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  M. Ziepert,et al.  Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[132]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.